Galera Therapeutics Inc. (OTC: GRTX)
$0.15
+0.0052 ( +3.71% ) 10.8M
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Market Data
Open
$0.15
Previous close
$0.14
Volume
10.8M
Market cap
$6.52M
Day range
$0.10 - $0.25
52 week range
$0.07 - $3.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jun 07, 2024 |
8-k | 8K-related | 13 | Jun 03, 2024 |
3 | Insider transactions | 1 | May 16, 2024 |
8-k | 8K-related | 15 | May 13, 2024 |
10-q | Quarterly Reports | 70 | May 13, 2024 |
8-k | 8K-related | 15 | May 03, 2024 |
4/a | Other | 1 | May 01, 2024 |
5 | Other | 1 | Apr 01, 2024 |
10-k | Annual reports | 86 | Mar 28, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |